Anatomic, morphologic and genetic heterogeneity of prostate cancer: implications for clinical practice

References

• Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod. Pathol. 18(8), 1022–1026 (2005).
   PubMedGoogle Scholar
• Cheng L, Poulos CK, Pan CX et al. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J. Urol. 174(3), 898–902 (2005).
   Google Scholar
• Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100(11), 2362–2366 (2004).
   PubMed Web of Science ®Google Scholar
• Eichelberger LE, Cheng L. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. Cancer 100(12), 2573–2576 (2004).
   PubMed Web of Science ®Google Scholar
• Cheng L, Song SY, Pretlow TG et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J. Natl Cancer Inst. 90(3), 233–237 (1998).
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Cheng L. Precursors of prostate cancer. Histopathology 60(1), 4–27 (2012).
   PubMed Web of Science ®Google Scholar
• McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am. J. Surg. Path. 12, 897–906 (1988).
   PubMed Web of Science ®Google Scholar
• Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2–ERG gene fusion. Mod. Pathol. 22(7), 866–871 (2009).
   Google Scholar
• Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum. Pathol. 41(6), 781–793 (2010).
   PubMed Web of Science ®Google Scholar
• Liu W, Laitinen S, Khan S et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15(5), 559–565 (2009).
   PubMed Web of Science ®Google Scholar
• Masterson TA, Cheng L, Mehan RM, Koch MO. Tumor focality does not predict biochemical recurrence after radical prostatectomy in men with clinically localized prostate cancer. J. Urol. 186(2), 506–510 (2011).
   PubMed Web of Science ®Google Scholar
• Masterson TA, Cheng L, Koch MO. Pathological characterization of unifocal prostate cancers in whole-mount radical prostatectomy specimens. BJU Int. 107(10), 1587–1591 (2011).
   PubMed Web of Science ®Google Scholar
• Eichelberger LE, Koch MO, Daggy JK, Ulbright TM, Eble JN, Cheng L. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am. J. Clin. Pathol. 120(3), 386–391 (2003).
   PubMed Web of Science ®Google Scholar
• Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM. Staging of prostate cancer. Histopathology 60(1), 87–117 (2012).
   PubMed Web of Science ®Google Scholar
• Eichelberger LE, Koch MO, Eble JN, Ulbright TM, Juliar BE, Cheng L. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod. Pathol. 18(7), 886–890 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng L, Davidson DD, Lin H, Koch MO. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cancer 110(9), 1967–1972 (2007).
   Google Scholar
• Cheng L, Koch MO, Juliar BE et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J. Clin. Oncol. 23(13), 2911–2917 (2005).
   Google Scholar
• Hattab EM, Koch MO, Eble JN, Lin H, Cheng L. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma. J. Urol. 175(5), 1695–1699; discussion 1699 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Cheng L, Blanca A, Montironi R. Cell proliferation and apoptosis in prostate needle biopsies with adenocarcinoma Gleason score 6 or 7. Anal. Quant. Cytol. Histol. 34(2), 61–65 (2012).
   Google Scholar
• Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 281(15), 1395–1400 (1999).
   PubMed Web of Science ®Google Scholar
• de la Rosette J, Ahmed H, Barentsz J et al. Focal therapy in prostate cancer-report from a consensus panel. J. Endourol. 24, 775–780 (2010).
   PubMed Web of Science ®Google Scholar
• Koch MO, Gardner T, Cheng L et al. Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer. J. Urol. 178(6), 2366–2370; discussion 2370 (2007).
   PubMed Web of Science ®Google Scholar
• Vlaeminck-Guillem V, Devonec M, Colombel M, Rodriguez-Lafrasse C, Decaussin-Petrucci M, Ruffion A. Urinary PCA3 score predicts prostate cancer multifocality. J. Urol. 185(4), 1234–1239 (2011).
   Google Scholar